Lakefront Biotherapeutics LKFT
EURONEXT · Netherlands · Health Technology
€26.12-0.30 (-1.14%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lakefront Biotherapeutics (LKFT) has a "meaningful opportunity" with its asset gamgertamig for the t
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines. Speaking at M
Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City at 5:35pm ET on Tuesday, September 15th, 2026. A live webcast of the presentation will be accessible on the Investors page of the Company’s website at Webcasts & Events - Lakefront Biotherapeutics. A replay of the webcast will be available following the comp
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.